Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPUF69
|
|||
| Drug Name |
N-Octyl-beta-valienamine
|
|||
| Synonyms |
(1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922580; N-Octylvalienamine; CHEMBL1234952; SCHEMBL21067585; BDBM50358322; DB08321; Q27097540; OEV
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gaucher disease [ICD-11: 5C56.0Y; ICD-9: 272.7] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H29NO4
|
|||
| Canonical SMILES |
CCCCCCCCNC1C=C(C(C(C1O)O)O)CO
|
|||
| InChI |
1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13-,14+,15+/m1/s1
|
|||
| InChIKey |
UPZUHYMBTUUPML-KBXIAJHMSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucosylceramidase (GBA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Other glycan degradation | |||
| Sphingolipid metabolism | ||||
| Metabolic pathways | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. | |||
| REF 2 | Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.